Association of prothrombin, FV Leiden and MTHFR gene polymorphisms in the Montenegrin patients with venous thromboembolism

Sladjana  Teofilov; Zvonko Magić; Olivera Miljanović; Tatjana Ostojić; Milena Bulatović

doi:10.2298/VSP190402086T

Sladjana Teofilov Clinical Center of Montenegro, Center for Medical Genetics and Immunology, Podgorica, Montenegro
Zvonko Magić Military Medical Academy, Institute of Medical Research, Belgrade, Serbia
Olivera Miljanović Clinical Center of Montenegro, Center for Medical Genetics and Immunology, Podgorica, Montenegro
Tatjana Ostojić Clinical Center of Montenegro, Center for Medical Genetics and Immunology, Podgorica, Montenegro
Milena Bulatović Clinical Center of Montenegro, Center for Medical Genetics and Immunology, Podgorica, Montenegro

DOI: https://doi.org/10.2298/VSP190402086T

Keywords: factor v, genes, mutation, polymorphism, genetic, prothrombin, thromboembolism

Abstract

Background/Aim. Polymorphisms of the factor V Leiden (FV G1691A), prothrombin (FII G20210A), and methylenetetrahydrofolate reductase (MTHFR C677T) genes are the most commonly investigated inherited risk factors for developing venous thromboembolism (VTE). Despite this fact, there is insufficient data regarding their clinical burden and distribution in the Montenegrin population. The aim of the study was to determine the frequency of these polymorphisms in Montenegrin patients with VTE. Methods. This case-control study was conducted on 160 Caucasian subjects. The study group was composed of 80 patients (35 men and 45 women) with VTE. The control group consisted of 80 healthy individuals (32 men and 48 women) without previous thromboembolic episodes. Genotyping of the FV G1691A, FII G20210A, and MTHFR C677T polymorphisms was performed by allele-specific polymerase chain reaction (PCR). Results. The frequency of heterozygotes (HET) for FII G20210A and FV G1691A was significantly higher in the VTE group compared to the healthy control group (χ² = 11.7; p = 0.001 and χ² = 17.69; p < 0.001, respectively). The association of FII G20210A and FV G1691A polymorphisms with an increased risk of VTE [odds ratio (OR) 10.5; 95% confidence interval (CI) = 2.34 to 47.27, and OR 14.8; 95% CI = 3.34 to 65.43; p < 0.001, respectively] was confirmed. Recessive homozygotes (RH) for FII G20210A and FV G1691A were not found in any of the investigated groups. Regarding MTHFR C677T, the difference between the frequency of HET and RH in the control and VTE group was not significant. Conclusion. Our study showed that FII G20210A and FV G1691A polymorphisms are significantly associated with VTE. Detection of the above-mentioned polymorphisms prior to VTE development can contribute to the prevention of further VTE occurrence, especially among patients' relatives who are carriers of these polymorphisms.

References

Rosendaal FR. Causes of venous thrombosis. Thromb J 2016; 14(Suppl 1): 24.

Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12(8): 464‒74.

Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8(10): 2105‒12.

Crous-Bou M, Harrington LB, Kabrhel C. Environmental and Genetic Risk Factors Associated with Venous Thromboembo-lism. Semin Thromb Hemost 2016; 42(8): 808‒20.

Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors for venous thromboembolism. Nat Rev Cardiol 2014; 11(3): 140‒56.

Cohoon KP, Heit JA. Inherited and Secondary Thrombophilia: Clinician Update. Circulation 2014; 129(2): 254‒7.

Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009; 23(5): 225–9.

De Stefano V. Inherited thrombophilia and life-time risk of venous thromboembolism: is the burden reducible? J Thromb Haemost 2004; 2(9): 1522‒5.

Segers O, Simioni P, Tormene D, Bulato C, Gavasso S, Rosing J, et al. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venousthrombosis in factor V Leiden heterozy-gotes. J Thromb Haemost 2012; 10(1): 73‒80.

Jiang J, Liu K, Zou J, Ma H, Yang H, Zhang X, et al. Associa-tions between polymorphisms in coagulation-related genes and venous thromboembolism: A meta-analysis with trial sequen-tial analysis. Medicine (Baltimore) 2017; 96(13): e6537.

Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Em-merich J, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Pro-thrombin 20210A and Methylenetetrahydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol 2013; 28(8): 621‒47.

Bezgin T, Kaymaz C, Akbal Ö, Yılmaz F, Tokgöz HC, Özdemir N. Thrombophilic Gene Mutations in Relation to Different Manifestations of Venous Thromboembolism: A Single Ter-tiary Center Study. Clin Appl Thromb Hemost 2018; 24(1): 100‒6.

Djordjevic V, Rakicevic Lj, Mikovic D, Kovac M, Miljic P, Ra-dojkovic D, et al. Prevalence of factor V Leiden, factor II G20210A and methylenetetrahydrofolate reductase in healthy and thrombophilic Serbian population. Acta Haematol 2004; 112(4): 227‒9.

Rietveld IM, Bos MHA, Lijfering WM, Li-Gao R, Rosendaal FR, Reitsma PH, et al. Factor V levels and risk of venous throm-bosis: The MEGA case-control study. Res Pract Thromb Haemost 2018: 2(2): 320‒6.

Bedencic M, Bozic M, Peternel P, Stegnar M. Major and potential prothrombotic genotypes in patients with venous thrombosis and in healthy subjects from Slovenia. Pathophysiol Haemost Thromb 2008; 36(2): 58‒63.

Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet 2015; 58(1): 1–10.

Zakai NA, McClure LA, Judd SE Safford MM, Folsom AR, Lutsey PL, et al. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circula-tion 2014; 129(14): 1502–9.

Adler G, Clark JS, Loniewska B, Czerska E, Salkic NN, Ciech-anowicz A. Prevalence of 1691G>A FV mutation in Poland compared with that in other Central, Eastern and South-Eastern European countries. Bosn J Basic Med Sci 2012; 12(2): 82‒7.

Cripe LD, Moore KD, Kane WH. Structure of the gene for hu-man coagulation factor V. Biochemistry 1992; 31(15): 3777‒85.

Zhang CL, Li ZM, Song ZH, Song T. Coagulation factor V gene 1691G>A polymorphism as an indicator for risk and progno-sis of lower extremity deep venous thrombosis in Chinese Han population. Medicine (Baltimore) 2018; 97(22): e10885.

Arsov T, Miladinova D, Spiroski M. Factor V Leiden Is Associ-ated with Higher Risk of Deep Venous Thrombosis of Large Blood Vessels. Croat Med J 2006; 47(3): 433‒9.

Kvasnička T, Hájková J, Bobčíková P, Cverhová V, Malíková I, Ul-rych J, et al. The frequencies of six important thrombophilic mutations in a population of the Czech Republic. Physiol Res 2014; 63(2): 245‒53.

Liao S, Woulfe T, Hyder S, Merriman E, Simpson D, Chunilal S. Incidence of venous thromboembolism in different ethnic groups: a regional direct comparison study. J Thromb Haemost 2014; 12(2): 214‒9.

Danckwardt S, Hentze MW, Kulozik AE. 3′ end mRNA pro-cessing: molecular mechanisms and implications for health and disease. EMBO J 2008; 27(3): 482‒98.

Jadaon MM. Epidemiology of Prothrombin G20210A Muta-tion in the Mediterranean Region. Mediterr J Hematol Infect Dis 2011; 3(1): e2011054.

Girolami A, Cosi E, Ferrari S, Girolami B. Prothrombin: An-other Clotting Factor After FV That Is Involved Both in Bleeding and Thrombosis. Clin Appl Thromb Hemost 2018; 24(6): 845‒9.

Ghaznavi H, Soheili Z, Samiei S, Soltanpour MS. Role of Hyper-homocysteinemia and Methylene Tetrahydrofolate Reductase C677T Polymorphism in Idiopathic Portal Vein Thrombosis. Vasc Specialist Int 2016; 32(1): 6‒10.

Brezovska-Kavrakova, J, Krstevska, M, Bosilkova, G, Alabakovska, S, Panov, S, Orovchanec, N. Hyperhomocysteinemia and of methylenetetrahydrofolate reductase (C677T) genetic poly-morphism in patients with deep vein thrombosis. Mater Soci-omed 2013; 25(3): 170‒4.

Rouhi-Broujeni H, Pourgheysari B, Hasheminia AM. Association of Homozygous Thrombophilia Polymorphisms and Venous Thromboembolism in Shahrekord, Iran. Tanaffos 2016; 15(4): 218‒24.

Alfirevic Z, Simundić AM, Nikolac N, Sobocan N, Alfirevi J, Stefa-novic M, et al. Frequency of factor II G20210A, factor V Lei-den, MTHFR C677T and PAI-1 5G/4G polymorphism in pa-tients with venous thromboembolism: Croatian case control study. Biochem Med 2010; 20(2): 229‒35.

Miljanović O, Magić Z, Teofilov S, Bulatović M, Likić D, Vojvodić D, et al. Association of thrombophilia with adverse pregnancy outcomes. Giorn It Ost Gin 2013, 35(1): 279‒81.

Miljanovic O, Dakić T, Teofilova S, Vojvodić D, Magic Z, Likic D. The FII2021G→A, FV Laiden and MTHFR 677C→T poly-morphisms and the risk of pregnancy loss, fetal malformations and chromosomal abnormalities. Med Data 2013; 5(3): 223‒9.

Jusić-Karić A, Terzić R, Jerkić Z, Avdić A, Pođanin M. Frequency and association of 1691 (G>A) FVL, 20210 (G>A) PT and 677 (C>T) MTHFR with deep vein thrombosis in the popula-tion of Bosnia and Herzegovina. Balkan J Med Genet 2016; 19(1): 43‒50.

Hotoleanu C, Trifa A, Popp R, Fodor D. The importance of ho-mozygous polymorphisms of methylenetetrahydrofolate reduc-tase gene in romanian patients with idiopathic venous throm-boembolism. Balkan Med J 2013; 30(2): 197–203.

Liu F, Silva D, Malone MV, Seetharaman K. MTHFR A1298C and C677T Polymorphisms Are Associated with Increased Risk of Venous Thromboembolism: A Retrospective Chart Review Study. Acta Haematol 2017; 138(4): 208‒15.